Can we predict who will beat liver cancer with immunotherapy?

NCT ID NCT06796114

Recruiting now Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Besancon Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study aims to find biological markers that can predict how well liver cancer patients respond to a combination of two immunotherapy drugs, tremelimumab and durvalumab. Researchers will follow 120 adults with advanced liver cancer who have not had prior systemic treatment. The goal is to improve personalized treatment decisions by identifying which patients are most likely to benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

CH de Chalon sur Saône
RECRUITING

Chalon-sur-Saône, France
CH de Mulhouse
RECRUITING

Mulhouse, France
CHU Grenoble
RECRUITING

Grenoble, France
CHU Poitiers
RECRUITING

Poitiers, France
CHU de Besançon
RECRUITING

Besançon, France
CHU de Reims
RECRUITING

Reims, France
Centre Paul Strauss
RECRUITING

Strasbourg, France
Hôpital Beaujon - APHP
RECRUITING

Paris, France
Hôpital Henri Mondor - APHP
RECRUITING

Paris, France
Hôpital La Pitié Salpêtrière - APHP
RECRUITING

Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.